Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)

ClinicalTrials.gov ID: NCT03665038

Public ClinicalTrials.gov record NCT03665038. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Brexanolone in the Treatment of Adolescent Female Subjects With Postpartum Depression

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multi-center study evaluating the safety, tolerability, and pharmacokinetics of brexanolone in the treatment of adolescent female participants with postpartum depression (PPD).

Study identification

NCT ID
NCT03665038
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Enrollment
28 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
15 Years to 17 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 7, 2018 (Actual)
Primary completion
Jan 8, 2021 (Actual)
Completion
Jan 8, 2021 (Actual)
Last update posted
Sep 15, 2025

2018 – 2021

United States locations

U.S. sites
17
U.S. states
9
U.S. cities
17
Facility City State ZIP Site status
Sage Investigational Site Tempe Arizona 85226 —
Sage Investigational Site North Little Rock Arkansas 72758 —
Sage Investigational Site Miramar Florida 33029 —
Sage Investigational Site Orlando Florida 32807 —
Sage Investigational Site Pensacola Florida 32502 —
Sage Investigational Site Pinellas Park Florida 33782 —
Sage Investigational Site Pompano Beach Florida 33060 —
Sage Investigational Site Atlanta Georgia 30331 —
Sage Investigational Site Decatur Georgia 30030 —
Sage Investigational Site Edgewood Kentucky 41017 —
Sage Investigational Site Owensboro Kentucky 42303 —
Sage Investigational Site Flowood Mississippi 39232 —
Sage Investigational Site Jackson Mississippi 39216 —
Sage Investigational Site Chapel Hill North Carolina 27599 —
Sage Investigational Site Middleburg Heights Ohio 44130 —
Sage Investigational Site Houston Texas 77058 —
Sage Investigational Site League City Texas 77573 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03665038, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 15, 2025 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03665038 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →